What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Ranjana H. Advani mostly deals with Internal medicine, Oncology, Lymphoma, Surgery and Immunology.
Her Internal medicine study frequently draws connections to adjacent fields such as Gastroenterology.
She has researched Oncology in several fields, including Clinical trial, Phases of clinical research, Bendamustine, Rituximab and Retrospective cohort study.
Her Lymphoma study combines topics in areas such as Cancer, Cancer research and Radiation therapy.
Ranjana H. Advani works mostly in the field of Surgery, limiting it down to concerns involving Cohort and, occasionally, Risk factor, Chemoradiotherapy, Multivariate analysis and Pleural effusion.
Her Immunology research incorporates elements of Agonist, Biopsy and Intensive care medicine.
Her most cited work include:
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms (3041 citations)
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma (1020 citations)
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies (831 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of investigation include Internal medicine, Oncology, Lymphoma, Rituximab and Surgery.
Ranjana H. Advani works mostly in the field of Internal medicine, limiting it down to topics relating to Gastroenterology and, in certain cases, Tolerability.
Her Oncology research is multidisciplinary, incorporating perspectives in Refractory, Radiation therapy, Immunology and Hodgkin lymphoma.
Her Lymphoma research includes elements of Cancer, BCL6 and Transplantation.
As part of one scientific family, Ranjana H. Advani deals mainly with the area of Rituximab, narrowing it down to issues related to the Vincristine, and often CHOP.
Her work deals with themes such as Clinical endpoint, Ibrutinib and Mantle cell lymphoma, which intersect with Phases of clinical research.
She most often published in these fields:
- Internal medicine (65.93%)
- Oncology (41.48%)
- Lymphoma (27.96%)
What were the highlights of her more recent work (between 2017-2021)?
- Internal medicine (65.93%)
- Oncology (41.48%)
- Lymphoma (27.96%)
In recent papers she was focusing on the following fields of study:
The scientist’s investigation covers issues in Internal medicine, Oncology, Lymphoma, Brentuximab vedotin and Hodgkin lymphoma.
Her research combines Gastroenterology and Internal medicine.
Her Oncology research includes themes of Blockade, Follicular lymphoma and Phases of clinical research.
Her studies deal with areas such as Prospective cohort study, BCL6 and Transplantation as well as Lymphoma.
Within one scientific family, she focuses on topics pertaining to Nivolumab under Brentuximab vedotin, and may sometimes address concerns connected to Ipilimumab.
Her Hodgkin lymphoma study integrates concerns from other disciplines, such as Advanced stage, Stanford V, Cohort and MEDLINE.
Between 2017 and 2021, her most popular works were:
- CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. (296 citations)
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (182 citations)
- Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (156 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Ranjana H. Advani focuses on Internal medicine, Oncology, Lymphoma, Brentuximab vedotin and Chemotherapy.
Her study on Internal medicine is mostly dedicated to connecting different topics, such as Gastroenterology.
Her Gastroenterology study combines topics from a wide range of disciplines, such as Febrile neutropenia, Neutropenia and Tolerability, Adverse effect.
The study incorporates disciplines such as Survival rate, Prospective cohort study, Clinical trial and Disease in addition to Oncology.
Her work carried out in the field of Lymphoma brings together such families of science as Blockade and Cancer research.
The concepts of her Brentuximab vedotin study are interwoven with issues in Chlorambucil, Nivolumab, Chemotherapy regimen and Doxorubicin.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
